Assetmark Inc. Has $54.17 Million Stock Position in Pfizer Inc. $PFE

Assetmark Inc. grew its stake in Pfizer Inc. (NYSE:PFE) by 9.6% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,234,608 shares of the biopharmaceutical company’s stock after purchasing an additional 195,624 shares during the period. Assetmark Inc.’s holdings in Pfizer were worth $54,167,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of PFE. Capital Advisors Inc. OK boosted its stake in Pfizer by 1.2% in the first quarter. Capital Advisors Inc. OK now owns 1,413,472 shares of the biopharmaceutical company’s stock worth $35,817,000 after purchasing an additional 17,032 shares in the last quarter. Westbourne Investments Inc. bought a new position in shares of Pfizer in the first quarter valued at about $2,411,000. Bourne Lent Asset Management Inc. lifted its position in Pfizer by 90.8% during the 2nd quarter. Bourne Lent Asset Management Inc. now owns 38,255 shares of the biopharmaceutical company’s stock worth $927,000 after buying an additional 18,200 shares in the last quarter. Strs Ohio bought a new stake in Pfizer during the 1st quarter worth about $49,968,000. Finally, IFM Investors Pty Ltd increased its position in Pfizer by 3.8% in the 2nd quarter. IFM Investors Pty Ltd now owns 1,127,143 shares of the biopharmaceutical company’s stock valued at $27,322,000 after acquiring an additional 41,263 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Trading Up 0.0%

NYSE PFE opened at $24.30 on Friday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The stock’s 50-day moving average is $24.80 and its 200-day moving average is $24.25. Pfizer Inc. has a one year low of $20.92 and a one year high of $28.64. The firm has a market cap of $138.15 billion, a P/E ratio of 12.93, a P/E/G ratio of 0.81 and a beta of 0.55.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. The firm had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business’s revenue was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be paid a $0.43 dividend. The ex-dividend date is Friday, November 7th. This represents a $1.72 annualized dividend and a yield of 7.1%. Pfizer’s payout ratio is presently 91.49%.

Analysts Set New Price Targets

Several research firms have issued reports on PFE. Citigroup upped their price objective on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Morgan Stanley reduced their target price on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a research note on Friday, October 10th. Bank of America increased their price objective on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a report on Friday, October 3rd. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Pfizer currently has a consensus rating of “Hold” and an average target price of $28.13.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.